A space-averaged maximum temperature of 3 3 eV with electron dens

A space-averaged maximum temperature of 3.3 eV with electron densities of the order of 10(17) cm(-3) was observed at a discharge time of 150 ns and a maximum discharge current of 200 A. One-dimensional dissipative magnetohydrodynamic (MHD) code was used to analyze the discharge dynamics in the gas-filled capillary discharge waveguide for high-intensity laser pulses. Simulations were performed for the conditions of the experiment. We compared the temporal behavior of the electron temperature and the radial electron density profiles, measured in the experiment with the results EMD 121974 of the numerical simulations. They occurred to be

in a good agreement. An ultrashort, intense laser pulse was guided by use of this plasma channel. (C) 2011 American Institute of Physics. [doi:10.1063/1.3560529]“
“A

device interrogation MAPK Inhibitor Library for a 32-year-old woman with arrhythmogenic right ventricular cardiomyopathy and an implantable cardioverter-defibrillator capable of monitoring intrathoracic impedance demonstrated a dramatic increase in her OptiVol Fluid index levels in the absence of clinical heart failure. The timing of her intrathoracic impedance changes correlated with plasma volume changes during an uneventful pregnancy without cardiovascular complications. The strengths and limitations of intrathoracic impedance are described in the context of the physiology of pregnancy. (PACE 2011; 34: e60-e63)”
“Purpose: To prospectively assess the incidence of delayed adverse reactions (DARs) in patients undergoing contrast material-enhanced computed tomography (CT) with the low osmolar nonionic contrast agent iohexol and compare with the incidence of DARs in patients undergoing unenhanced CT as control subjects.

Materials and Methods: Institutional review board approval and informed written consent for this prospective study were obtained.

The study was HIPAA compliant. Patients undergoing CT for routine indications were enrolled from a random next-available scheduling template by an on-site clinical trials monitor. All subjects received a questionnaire asking them to indicate any DAR occurring later than 1 hour after their examination. Sixteen manifestations were listed Selleck BIX-01294 and included rash, skin redness, skin swelling, nausea, vomiting, and dizziness, among others. To ensure maximal surveillance, a clinical trials coordinator initiated direct telephone contact for further assessment. Patients suspected of having moderately severe cutaneous reactions were invited to return for a complete dermatologic clinical assessment including skin biopsy, if indicated. Statistical analysis was performed by using a two-sided Wilcoxon-Mann-Whitney test, a logistic regression utilizing a chi(2) test to adjust for sex and age, and a two-sided Fisher exact test.

Results: A total of 539 patients (258 receiving iohexol and 281 not receiving contrast material) were enrolled. DARs were observed in 37 (14.3%) of 258 subjects receiving iohexol and in seven (2.

Comments are closed.